Riskpilot← Back to searchSign inGet full accessCLINICAL INNOVATION ApS
APSActiveCVR 29924880Ydervang 5Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20065 employeeswww.clinicalinnovation.dk
Revenue 2025
DKK 2,8M
+25% vs 2024
EBITDA margin
29.3%
+81% vs 2024
Equity ratio
39.2%
Financial strength
Net profit 2025
DKK 414K
+332% vs 2024
| Revenue | DKK 2,8M | +25% |
| EBITDA | DKK 815K | +81% |
| Net profit | DKK 414K | +332% |
| Total assets | DKK 9,7M | +1% |
| Equity | DKK 3,8M | +2% |
| Employees | 5 | — |
Legal name
CLINICAL INNOVATION ApS
CVR number
29924880
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
29. september 2006
Share capital
DKK 126.000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-09-30
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør eller af 2 medlemmer af bestyrelsen i forening.
Company purpose
Selskabets formål er handel og industri, herunder engroshandel med medicinalvarer og sygeplejeartikler samt anden i forbindelse hermed stående virksomhed.
Address
Ydervang 5
Phone
+4533791370
Email
info@clinicalinnovation.dk
Website
www.clinicalinnovation.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.368 | 3.022 | 2.821 | 3.203 | 3.923 | 3.721 | 3.985 | 3.732 | 3.946 | 3.977 | 3.413 | 2.310 | 2.217 | 2.776 |
| Staff expenses | -1.390 | -1.965 | -1.922 | -2.572 | -2.570 | -3.043 | -3.055 | -3.450 | -2.715 | -2.809 | -3.054 | -1.939 | -1.375 | -1.961 |
| EBITDA | 978 | 1.057 | 899 | 630 | 1.330 | 603 | 930 | 282 | 1.231 | 1.168 | 360 | 306 | 450 | 815 |
| Depreciation & amort. | 155 | -188 | -175 | -134 | -175 | -163 | -191 | -153 | -320 | -292 | -173 | -149 | -135 | -20 |
| EBIT | 824 | 869 | 724 | 496 | 1.155 | 440 | 739 | 129 | 911 | 876 | 187 | 158 | 315 | 794 |
| Net financials | -83 | -141 | -80 | -129 | -155 | -133 | -187 | -103 | -127 | -118 | -127 | -151 | -246 | -260 |
| Profit before tax | 741 | 728 | 644 | 367 | 1.000 | 307 | 552 | 26 | 784 | 758 | 60 | 6 | 69 | 535 |
| Tax | 190 | 183 | 161 | 95 | 246 | 64 | 135 | 11 | 191 | 197 | 19 | 14 | -26 | 121 |
| Net profit | 550 | 545 | 483 | 272 | 754 | 243 | 417 | 15 | 593 | 562 | 41 | -7 | 96 | 414 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 4.819 | 5.628 | 5.804 | 7.957 | 7.280 | 7.664 | 7.432 | 7.575 | 7.369 | 7.525 | 8.122 | 8.336 | 9.632 | 9.739 |
| Equity | 2.428 | 2.588 | 2.878 | 3.084 | 2.923 | 3.013 | 3.230 | 3.044 | 3.567 | 3.629 | 3.670 | 3.662 | 3.758 | 3.822 |
| Long-term debt | 168 | 199 | 187 | 116 | 1.432 | 969 | 705 | 275 | 297 | 192 | 13 | 0 | 0 | 0 |
| Short-term debt | 2.190 | 2.824 | 2.739 | 4.757 | 2.925 | 3.682 | 3.497 | 4.256 | 3.505 | 3.703 | 4.439 | 4.674 | 5.874 | 5.917 |
| Total debt | 2.358 | 3.023 | 2.926 | 4.873 | 4.357 | 4.651 | 4.202 | 4.531 | 3.802 | 3.896 | 4.452 | 4.674 | 5.874 | 5.917 |
EBITDA margin
29.3%
This company
15.8%
Market median
+85% vs market
20122025
Equity ratio
39.2%
This company
38.2%
Market median
+3% vs market
20122025
Return on equity
10.8%
This company
18.4%
Market median
+41% vs market
20122025
Net profit margin
14.9%
This company
8.1%
Market median
+84% vs market
20122025
Asset turnover
0.29×
This company
1.12×
Market median
-74% vs market
20122025
Debt / equity
1.55×
This company
0.62×
Market median
-150% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via CVR / Virk · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via CVR / Virk · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via CVR / Virk · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via CVR / Virk · Period 2020-10-01 – 2021-09-30
- Annual report 2020Filed via CVR / Virk · Period 2019-10-01 – 2020-09-30
- Annual report 2019Filed via CVR / Virk · Period 2018-10-01 – 2019-09-30
- Annual report 2018Filed via CVR / Virk · Period 2017-10-01 – 2018-09-30
- Annual report 2017Filed via CVR / Virk · Period 2016-10-01 – 2017-09-30
- Annual report 2016Filed via CVR / Virk · Period 2015-10-01 – 2016-09-30
- Annual report 2015Filed via CVR / Virk · Period 2014-10-01 – 2015-09-30
- Annual report 2014Filed via CVR / Virk · Period 2013-10-01 – 2014-09-30
- Annual report 2013Filed via CVR / Virk · Period 2012-10-01 – 2013-09-30
- Annual report 2012Filed via CVR / Virk · Period 2011-10-01 – 2012-09-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CM Management | Management | 2006 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2006 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2006 | — | — | |
| Board of Directors | 2006 | — | — | |
| Chairman | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
PIA & CLAUS DINESEN HOLDING ApS | Company | 100.0% | 100.0% | 2017 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
PIA & CLAUS DINESEN HOLDING ApS
CLINICAL INNOVATION ApS Board members of CLINICAL INNOVATION ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Claus Michael Dinesen | Management | 0 companies |
| Henning Langberg | Board of Directors | 0 companies |
| Magnus Oliver Lorentzen Dinesen | Board of Directors | 0 companies |
| Marc Phillip Gall Schultz Lorentzen | Board of Directors | 0 companies |
| Pia Dinesen | Board of Directors | 0 companies |
| Annelise Høy Madsen | Board of Directors | 0 companies |
| Ole Hedemann | Chairman | 0 companies |